How a Trip Can Break a Habit

Addiction is not a failure of character; it is a form of learning that worked too well. The brain is built to notice what brings relief and to carve a fast, automatic path back to it — and a drug hijacks that machinery, teaching the reward system that nothing on earth matters more than the next dose. The cruel part is how durable that lesson is. Which is exactly why the psychedelic results are so disorienting: they suggest that a single, overwhelming afternoon can do what years of daily medication struggle to do — not by blocking the drug, but by briefly unlocking the brain and giving a person the chance to learn something new.

The smokers who quit

Start with the study that made the field pay attention. In 2014, Matthew Johnson, Albert Garcia-Romeu and colleagues at Johns Hopkins took fifteen nicotine-dependent smokers — people averaging nineteen cigarettes a day for thirty-one years, with roughly six failed quit attempts behind them — and embedded two to three psilocybin sessions inside a fifteen-week cognitive-behavioral quit program. The result was almost hard to publish for how large it was: twelve of the fifteen (80%) were biologically confirmed smoke-free at six months (Johnson et al., 2014). For comparison, even the best conventional treatments — patches, varenicline, intensive counseling — rarely clear 35%. A follow-up found 67% still abstinent at twelve months, and 60% at an average of thirty months out (Johnson et al., 2017). Tellingly, 87% rated the psilocybin sessions among the five most personally meaningful experiences of their lives. That last number is not a footnote — as we’ll see, the depth of the experience kept predicting who stayed quit.

The honest caveat has to come immediately, because it is the whole game here: this was a small, open-label, uncontrolled pilot. Fifteen people, everyone knew they got the drug, no placebo group. That design can generate a dazzling number and still be wrong about the true effect size. It is a reason to run bigger trials, not a reason to book a session. Which is exactly why the alcohol work matters more.

The first real trial

In 2022, Michael Bogenschutz and colleagues at NYU published what the smoking study lacked: a proper double-blind, randomized, placebo-controlled trial — the first of its kind for psilocybin in addiction. Ninety-five adults with alcohol use disorder received twelve weeks of psychotherapy plus two day-long medication sessions, randomized to psilocybin or to an active placebo (diphenhydramine, chosen because it produces noticeable effects and helps preserve the blind). Over the following eight months, the psilocybin group spent far less time drinking heavily: heavy-drinking days fell to 9.7%, versus 23.6% on placebo — a 13.9 percentage-point difference, with no serious adverse events in the psilocybin arm (Bogenschutz et al., JAMA Psychiatry 2022). This is the strongest single piece of evidence in the entire field: randomized, blinded, active-placebo controlled. The nuance the authors themselves stress is that it tested psilocybin plus psychotherapy — the drug was never handed over alone, and the effect belongs to the package, not the molecule in isolation.

An old idea, rediscovered

None of this is actually new. In the 1950s, the psychiatrists Humphry Osmond and Abram Hoffer were treating alcoholism with LSD in Saskatchewan, working from a striking hypothesis: that a single, ego-shattering psychedelic experience might mimic the “hitting bottom” spiritual conversion that sometimes let people in Alcoholics Anonymous suddenly stop. (Osmond, corresponding with Aldous Huxley, coined the very word psychedelic in 1957.) For decades that work was dismissed as a countercultural curiosity — until Teri Krebs and Pål-Ørjan Johansen went back and did the math. Their 2012 meta-analysis pooled six randomized controlled trials, 536 patients, from the 1960s and 70s, and found that a single dose of LSD produced a significant benefit: an odds ratio of 1.96 (95% CI 1.36–2.84) for reduced alcohol misuse, strongest in the months after dosing and fading by around a year (Krebs & Johansen, 2012). Two generations apart, using different drugs and different scientists, the signal keeps pointing the same way.

Ibogaine and the opioid problem

The hardest form of dependence — opioids — has its own, far riskier candidate. Ibogaine, an alkaloid from the West African iboga shrub, is unusual: within hours it can collapse acute withdrawal and blunt craving, seemingly “resetting” the opioid system. In a prospective observational study of thirty opioid-dependent people, withdrawal scores fell from 31 to 14 in about seventy-six hours, and half reported no opioid use at all one month later (Brown & Alper, 2018); a New Zealand study following fourteen people for a full year found a single treatment produced sustained reductions in use (Noller et al., 2018). Some of that durability is chemistry: ibogaine is converted to noribogaine, a long-lived metabolite thought to carry much of the anti-craving effect.

But ibogaine is genuinely dangerous, and this cannot be softened. It and noribogaine block the heart’s hERG potassium channel, prolonging the QT interval and risking fatal arrhythmia for days after a dose. A forensic review documented nineteen deaths associated with ibogaine between 1990 and 2008, most involving pre-existing heart disease or drug combinations (Alper, Stajić & Gill, 2012), and the count has grown since — almost all in unregulated clinics without cardiac monitoring. Ibogaine is Schedule I in the United States. The observational results are real; so are the bodies. Both belong in the same sentence.

Why one session can matter: the plasticity window

So what could possibly let a single experience move a decades-old habit? The emerging answer is neuroplasticity — a brief reopening of the brain’s capacity to rewire. Classic psychedelics act at the 5-HT2A receptor, and switching it on does more than alter perception. In a landmark study, Calvin Ly and colleagues showed that psychedelics physically increase the density of dendritic spines and synapses on cortical neurons — in some assays more potently than ketamine — an effect that vanished when BDNF or mTOR signaling was blocked. They coined a name for such molecules: psychoplastogens (Ly et al., 2018). More provocatively, Romain Nardou and colleagues found that a whole class of psychedelics can reopen a “critical period” for social reward learning in mice — a window the brain normally slams shut after youth — and that the length of the reopening tracked how long each drug’s subjective effects last in humans (Nardou et al., 2023). Read that across to addiction and you get the working hypothesis: the drug does not erase the habit, it briefly makes the brain plastic again — teachable — and the therapy around it supplies the new lesson.

That plasticity acts on a well-mapped circuit. Addiction runs on the mesolimbic dopamine pathway — the reward line from the midbrain to the nucleus accumbens — with the prefrontal cortex (top-down control) worn down and the dorsal striatum (automatic habit) overgrown, all of it inflamed by cue-triggered craving (the framework of Koob and Volkow). Notably, the nucleus accumbens is exactly where Nardou’s critical-period reopening occurred. A psychedelic, on this view, is a system-wide plasticity signal delivered to a circuit that has become rigidly overtrained — a chance to loosen the groove. (Caveat: the elegant “default-mode-network reset” story you may have heard is best evidenced in depression imaging and is extrapolated to addiction; treat it as a leading hypothesis, not a proven mechanism.)

The experience is part of the medicine

Here is the finding that keeps the story from being purely pharmacological. Across these trials, the people who did best were the ones who had the deepest experience. In the smoking cohort, participants who reported a full “mystical” experience — the dissolution of self, unity, a sense of encountering something profoundly meaningful — were significantly more likely to still be abstinent months later (Garcia-Romeu et al., 2014). In the alcohol pilot, the sheer intensity of the acute experience predicted later drinking reductions with correlations as high as 0.76–0.89 (Bogenschutz et al., 2015). This is why the field insists the psychedelic is not a pill you swallow and forget. The molecule opens a window; the experience — the reckoning, the reframing, the new sense of what a life could be — is what walks through it. Set, setting, preparation and integration are not garnish. They are the active ingredients as much as the drug.

The honest ledger

So: is addiction solved? No — and pretending otherwise betrays the science. The most-quoted figures (the 80%, the ten-person alcohol pilot) come from tiny, open-label studies that inflate effects; the one rigorous double-blind trial shows a real but partial benefit, achieved with intensive therapy. People almost always know whether they got a psychedelic, which biases every subjective outcome. Not everyone responds, bad experiences happen, and classic psychedelics carry real contraindications — a personal or family history of psychosis or bipolar disorder, certain cardiac conditions, serotonergic drug interactions. Ibogaine can stop your heart. And yet, with all of that on the table, the pattern is remarkably consistent across seventy years, multiple drugs, and independent labs: a guided psychedelic experience, wrapped in real psychological support, can help some people put down a dependence that nothing else could move. Not because it deletes the craving, but because for a few hours it makes the brain young enough to learn a different way to live — and gives the person a reason to.

OOTW Journal is educational and does not provide medical advice. Psychedelics remain controlled substances in most countries and are not safe for everyone. Ibogaine in particular carries a risk of fatal cardiac arrhythmia and should never be used outside medical supervision. Nothing here is a recommendation to use any psychedelic, and addiction is a serious medical condition — if you are struggling, please reach out to a qualified professional.